Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis

Fig. 2

Serum PF-06835375 concentration–time profiles in the A single ascending dose and B multiple ascending dose cohorts (pharmacokinetic analysis population). The PK analysis population included all patients who received at least one dose of the study treatment and had evaluable PK data. The plots presented are semi-logarithmic. IV intravenous, MAD multiple ascending dose, PK pharmacokinetic, SAD single ascending dose, SC subcutaneous

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us